Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01199367 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer
A Phase 1 study, sponsored by Kyowa Kirin Co..
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01199367 is a Phase 1 study that was terminated before completion, run by Kyowa Kirin Co.. The registered enrollment target is 11 participants.
The verdict
NCT01199367, a Phase 1 study, was terminated before completion, sponsored by Kyowa Kirin Co..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study will determine the highest dose of KW-2450 in combination with lapatinib and letrozole that can be administered safely to subjects with advanced or metastatic breast cancer and to evaluate its effectiveness. This study was terminated in Phase 1 and never proceeded to the Phase 2 portion of the study.
Interventions
- DRUG KW-2450 in combination with lapatinib and letrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01199367
The ClinicalTrials.gov registry entry for NCT01199367 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin Co., which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KW-2450 in combination with lapatinib and letrozole is the first listed.
NCT01199367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01199367 about?
NCT01199367 is a clinical study titled "Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer". This study will determine the highest dose of KW-2450 in combination with lapatinib and letrozole that can be administered safely to subjects with advanced or metastatic breast cancer and to evaluate its effectiveness. This study was terminated in Phase 1 and never proceeded to the Phase 2 portion ...
What is the current status of trial NCT01199367?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2010-12. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01199367?
The interventions under investigation include: KW-2450 in combination with lapatinib and letrozole (DRUG).
Who is sponsoring clinical trial NCT01199367?
This trial is sponsored by Kyowa Kirin Co., which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.